• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Do those who were retained feel safe?









That's funny. No one, in this industry, is safe. We just have the last deck chairs on the Titanic. It's eventually all going down. Whether that's 6 months or a year from now no one knows but it's coming.
 




























You can really feel safe if you are the last man in the territory (literally no other rep of any kind around) and your territory has been consolidated with at least 3 or 4 neighboring territories (basically 1/3 of the state or total metro area)..then you should be all right.
 








You can really feel safe if you are the last man in the territory (literally no other rep of any kind around) and your territory has been consolidated with at least 3 or 4 neighboring territories (basically 1/3 of the state or total metro area)..then you should be all right.

If you had the whole country you are not safe. There is nothing to sell!
 








What's really really funny are females that think because they've won PC, CS in the past but got a 1 ranking -- are "protected" They deserve the ranking they got, and they deserve to be let go.
 




What's really really funny are females that think because they've won PC, CS in the past but got a 1 ranking -- are "protected" They deserve the ranking they got, and they deserve to be let go.

What is really, really funny is watching all you jerks who have made "money for nothin' and chicks for free" trying to pretend that you have anything to laugh at . . . . hahahahahaa
 








Novartis as a whole does have a few promising specialty products coming in the next few years. unfortunately the only thing slated for primary care is the COPD portfolio and the estimated time on that is 2015-2016. By my estimate, that leaves us with nothing to sell for a year unless we buy something. The most likely scenario is we are gone in 6-12 months.
 




It makes sense for Nov to become a highly skilled specialty company. Primary care with the smiling sycophants that make up the field force now are not qualified for the future in medicine, regardless of what happens with health care. They have run the course of a career that is not viable, and the brighter ones will be planning for their futures
 




But I don't understand. NVS's stock price keeps going up and the analysts are all very bullish on it. They are saying that overall sales will keep up a steady increase?

The answer is Obamacare - millions of new patients buying generics and NVS does't need pharma sales for that. I hope that your 401k full of NVS stock tides you over until your SS retirement kicks in!
 




Safe, really? What you gonna sell in that territory 6-12 mo from now?

This kind of analysis is from a point of view from the old regulatory environment.

Then, even if you had a product to sell that had a generic competitor you could count on some sales to sneak in and thus you could keep your job.

Now, post Obamacare, there is a new market dynamic due to the new regulatory climate. NVS, and all big Pharmas, have a big financial disincentive, selling products that have a generic competitor. Now anyone with private healthcare insurance, if a doc writes a script for a drug that NVS sells and that drug has a generic equivalent - pays a rebate to the govt.

So, even if you "have a product to sell" the model of selling it has changed because it is much more likely that NVS's margin on this product is much smaller than before Obamacare.

Insider hint - the rebate Pharma is forced to pay for the sale of drugs that a generic equivalent is about the cost of selling that drug through a Rep market. The Pharma;s negotiated it that way so that, during the transition period between the market now where they have many drugs with that kind of competition, and the steady state market in the future where there is none, they can find sales models that do not require the expense of a Rep selling them, then they can get rid of the Reps and hold their margins.

The bet is that, with fewer Reps pushing these in the market their sales will gradually decline but in the mean time Pharma will sell them at the same margin until they are at the same price as their generic competitors.

The Reps selling these drugs now are "road kill" on the path to the future pharma market in the US.